Medicare Rights Center flags cost-sharing limits in the GLP-1 Bridge Program

The Medicare Rights Center is warning that the flat $50 monthly copay inside Medicare's new GLP-1 Bridge Program does not work like ordinary Medicare drug coverage. Because the program sits outside the Part D benefit, the $50 payment does not count toward a Part D deductible or the annual out-of-pocket limit, Extra Help cannot be applied to it, and the amount stays $50 no matter what stage of Part D a person is in ^[1].

The Bridge Program starts July 1, 2026, and runs through December 31, 2027 ^[1]. It covers three products: Wegovy (semaglutide) injections and tablets, Zepbound (tirzepatide) in the KwikPen, and Foundayo (orforglipron) ^[1].

To qualify, a person must be 18 or older, need the medication for weight loss and keeping weight off, and meet at least one weight and health criterion. Those are a BMI of 35 or higher; a BMI of 30 or higher along with a condition such as heart failure, uncontrolled hypertension or chronic kidney disease; or a BMI of 27 or higher along with risks such as pre-diabetes, a prior heart attack or peripheral artery disease ^[1]. A person also must have Medicare with drug coverage, either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage, and must receive prior authorization from the Bridge Program ^[1].

The program is not run through Part D plans. Part D plans do not have to sign up or participate, and a central system run by Medicare handles approvals, processes claims and pays pharmacies ^[1].

Federal law generally bars Part D plans from covering drugs prescribed for weight loss, so Medicare cannot simply add these medicines to the standard benefit without Congress acting ^[1]. The Centers for Medicare & Medicaid Services instead created two test models: the GLP-1 Bridge Program and the Better Approaches to Lifestyle and Nutrition for Comprehensive Health, or BALANCE, model, which would have let Part D plans opt in to covering GLP-1 drugs for weight loss ^[1]. In May 2026, CMS said the Part D portion of BALANCE would be delayed indefinitely and that the Bridge would be extended through December 31, 2027 ^[1].

The prior authorization process was not fully open as of early June 2026, according to the Medicare Rights Center, which said more information was expected that month and that prior authorizations would be accepted and processed starting July 1, 2026 ^[1].

Why it matters for patients

A fixed $50 a month is easy to understand, but it can land differently depending on a person's income and other drug costs. People who receive Extra Help, or who normally pay little or nothing under Part D once they reach the annual out-of-pocket cap, would still owe $50 each month under the Bridge, because Extra Help does not apply and the copay does not change at any stage of the benefit ^[1].

Money paid through the Bridge also does not count toward the Part D deductible or the out-of-pocket limit, so those payments do not move a person closer to the point where other Part D drugs become cheaper ^[1]. The Medicare Rights Center says these features make it vital for interested Medicare enrollees to thoroughly weigh the pros and cons of using the Bridge Program to get these medications ^[1].

Eligibility is also tied to the weight-loss indication, and the program is temporary. It is not yet known what coverage, if any, would follow the current end date of December 31, 2027, or how approvals will work in practice once the program is running ^[1].

What happens next

July 1, 2026: the Bridge Program begins, and prior authorizations are accepted and processed ^[1].

May 2026 onward: the Part D portion of the BALANCE model is delayed indefinitely, and the Bridge continues through December 31, 2027 ^[1].